Podoplanin (PDPN) is known to be expressed in normal tissues, including lymphatic endothelial cells, renal podocytes, and type I lung alveolar cells. Monoclonal antibodies (mAbs) against human, mouse, rat, rabbit, dog, cat, and bovine PDPN have already been established; however, mAbs against pig PDPN (pPDPN) are lacking. In the present study, mice were immunized with pPDPN-overexpressing Chinese hamster ovary (CHO)-K1 cells (CHO/pPDPN), and hybridomas producing mAbs against pPDPN were identified by flow cytometric screening. One of the mAbs, PMab-213 (IgG2b, kappa), could specifically detect CHO/pPDPN cells through flow cytometry and detect pPDPN through western blot analysis. KD of PMab-213 for CHO/pPDPN was determined to be 2.1 × 10−9 M, indicating a high affinity for CHO/pPDPN. Furthermore, PMab-213 strongly stained lymphatic endothelial cells, renal podocytes, and type I lung alveolar cells through immunohistochemistry. PMab-213 is expected to be useful in investigating the function of pPDPN.
Get full access to this article
View all access options for this article.
References
1.
Breiteneder-GeleffS, MatsuiK, SoleimanA, MeranerP, PoczewskiH, KaltR, SchaffnerG, and KerjaschkiD: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol, 1997; 151:1141–1152.
2.
Breiteneder-GeleffS, SoleimanA, KowalskiH, HorvatR, AmannG, KriehuberE, DiemK, WeningerW, TschachlerE, AlitaloK, and KerjaschkiD: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol, 1999; 154:385–394.
3.
MishimaK, KatoY, KanekoMK, NishikawaR, HiroseT, and MatsutaniM: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol, 2006; 111:483–488.
4.
MishimaK, KatoY, KanekoMK, NakazawaY, KunitaA, FujitaN, TsuruoT, NishikawaR, HiroseT, and MatsutaniM: Podoplanin expression in primary central nervous system germ cell tumors: A useful histological marker for the diagnosis of germinoma. Acta Neuropathol, 2006; 111:563–568.
5.
KatoY, VaidyanathanG, KanekoMK, MishimaK, SrivastavaN, ChandramohanV, PegramC, KeirST, KuanCT, BignerDD, and ZalutskyMR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. Nucl Med Biol, 2010; 37:785–794.
6.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
7.
Ochoa-AlvarezJA, KrishnanH, PastorinoJG, NevelE, KephartD, LeeJJ, RetzbachEP, ShenY, FatahzadehM, BaredesS, KalyoussefE, HonmaM, AdelsonME, KanekoMK, KatoY, YoungMA, Deluca-RaponeL, ShienbaumAJ, YinK, JensenLD, and GoldbergGS: Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget, 2015; 6:9045–9060.
8.
SchoppmannSF, JeschB, RieglerMF, MaroskeF, SchwameisK, JomrichG, and BirnerP: Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus. Clin Exp Metastasis, 2013; 30:441–446.
9.
KatoY, KanekoM, SataM, FujitaN, TsuruoT, and OsawaM: Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol, 2005; 26:195–200.
10.
KimuraN, and KimuraI: Podoplanin as a marker for mesothelioma. Pathol Int, 2005; 55:83–86.
11.
AbeS, MoritaY, KanekoMK, HanibuchiM, TsujimotoY, GotoH, KakiuchiS, AonoY, HuangJ, SatoS, KishukuM, TaniguchiY, AzumaM, KawazoeK, SekidoY, YanoS, AkiyamaS, SoneS, MinakuchiK, KatoY, and NishiokaY: A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody. J Immunol, 2013; 190:6239–6249.
AriizumiT, OgoseA, KawashimaH, HottaT, LiG, XuY, UmezuH, SugaiM, and EndoN: Expression of podoplanin in human bone and bone tumors: New marker of osteogenic and chondrogenic bone tumors. Pathol Int, 2010; 60:193–202.
14.
KunitaA, KashimaTG, OhazamaA, GrigoriadisAE, and FukayamaM: Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol, 2011; 179:1041–1049.
15.
KatoY, SasagawaI, KanekoM, OsawaM, FujitaN, and TsuruoT: Aggrus: A diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene, 2004; 23:8552–8556.
16.
KatoY, KanekoMK, KunitaA, ItoH, KameyamaA, OgasawaraS, MatsuuraN, HasegawaY, Suzuki-InoueK, InoueO, OzakiY, and NarimatsuH: Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci, 2008; 99:54–61.
17.
KunitaA, KashimaTG, MorishitaY, FukayamaM, KatoY, TsuruoT, and FujitaN: The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol, 2007; 170:1337–1347.
18.
KatoY, FujitaN, KunitaA, SatoS, KanekoM, OsawaM, and TsuruoT: Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem, 2003; 278:51599–51605.
19.
KanekoMK, KatoY, KitanoT, and OsawaM: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 2006; 378:52–57.
20.
Martin-VillarE, SchollFG, GamalloC, YurritaMM, Munoz-GuerraM, CrucesJ, and QuintanillaM: Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer, 2005; 113:899–910.
21.
KanekoMK, KunitaA, AbeS, TsujimotoY, FukayamaM, GotoK, SawaY, NishiokaY, and KatoY: Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci, 2012; 103:1913–1919.
22.
Suzuki-InoueK, KatoY, InoueO, KanekoMK, MishimaK, YatomiY, YamazakiY, NarimatsuH, and OzakiY: Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem, 2007; 282:25993–26001.
23.
NagaeM, Morita-MatsumotoK, KatoM, KanekoMK, KatoY, and YamaguchiY: A platform of C-Type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure, 2014; 22:1711–1721.
KajiC, TsujimotoY, Kato KanekoM, KatoY, and SawaY: Immunohistochemical examination of novel rat monoclonal antibodies against mouse and human podoplanin. Acta Histochem Cytochem, 2012; 45:227–237.
26.
OkiH, HonmaR, OgasawaraS, FujiiY, LiuX, TakagiM, KanekoMK, and KatoY: Development of sensitive monoclonal antibody PMab-2 against rat podoplanin. Monoclon Antib Immunodiagn Immunother, 2015; 34:396–403.
27.
HonmaR, FujiiY, OgasawaraS, OkiH, LiuX, NakamuraT, KanekoMK, TakagiM, and KatoY: Establishment of a novel monoclonal antibody PMab-32 against rabbit podoplanin. Monoclon Antib Immunodiagn Immunother, 2016; 35:41–47.
28.
HonmaR, KanekoMK, OgasawaraS, FujiiY, KonnaiS, TakagiM, and KatoY: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal antibody PMab-38 in immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2016; 35:212–216.
29.
YamadaS, ItaiS, NakamuraT, YanakaM, SaidohN, ChangYW, HandaS, HaradaH, KagawaY, IchiiO, KonnaiS, KanekoMK, and KatoY: PMab-52: Specific and sensitive monoclonal antibody against cat podoplanin for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:224–230.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
32.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
33.
YamadaS, ItaiS, NakamuraT, YanakaM, ChangYW, SuzukiH, KanekoMK, and KatoY: Monoclonal antibody L1Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib Immunodiagn Immunother, 2018; 37:110–115.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
